A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 636 participants.
Also called NCT03861052
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 636 participants
- Sponsor
- Registry
-
NCT03861052
-
- Other papers using this trial's data
- Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT03861052. Randomized; double masking; primary purpose treatment. Start 2019-05-07 (actual); primary completion 2021-03-10 (actual). Results posted on 2022-04-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes
- Acronym
- SURPASS J-mono
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Tirzepatide
- Intervention (Drug)
- Dulaglutide
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct03861052- Content hash
f16ed8401fdfbdde7cc888f7278a53b018a60f6b7e3203c14b09f3ee34c2ae3f